Companies Cryptocurrencies
Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc
Exchange: NasdaqGS
IPO Date: 03/04/2020
CEO: Dr. Anthony Y. Sun M.D.
Biotechnology Healthcare 🔗
  • ZNTL
    symbol
  • 77.69
    price
  • 3500160000
    market cap
  • 2.1500015
    changes
If you bought

shares of Zentalis Pharmaceuticals Inc (ZNTL) on
You would have made
AMOUNT
today.
Old Price $12 Current Price $12

Zentalis Pharmaceuticals, Inc., formerly Zentalis Pharmaceuticals LLC., is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative. Its other products include ZN-c3, an oral and small molecule inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of cell lung cancer.

Address: 530 Seventh Avenue Suite 2201 New York City NEW YORK 10018

Stay updated.